Criteria for Vancomycin Serum Trough Concentration Monitoring
deteriorating/unstable renal function (increase in baseline Scr of ≥ 40 µmol/L, or 50% of baseline)
morbidly obese patients [≥ 190% IBW or BMI ≥ 40kg/m2]
patients with anticipated therapy ≥ 7 days
patients who are severely ill (i.e. sepsis)
patients with altered volume of distribution or clearance of vancomycin (e.g. cystic fibrosis, pediatrics, elderly > 60 years, cancer, burns > 20% BSA)
selected dialysis patients [e.g. high flux and continuous hemodialysis/filtration (CAVH, CVVH, CVVHDF)]